La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Clearside Biomedical a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Clearside Biomedical..

Clearside Biomedical (NASDAQ:CLSD) Azioni, Catena delle Opzioni

Clearside Biomedical

Clearside Biomedical Inc is a United States-based clinical biopharmaceutical company. It is engaged in developing pharmacological therapies to treat blinding disease of the eye through the suprachoroidal space, or SCS. The company's novel SCS injection platform, utilizing proprietary SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases.

Clearside Biomedical, Inc. - Common Stock

Clearside Biomedical Inc

Oppenheimer analyst Owen Lau maintains Coinbase Glb (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) with a Outperform and raises the price target from $265 to $358.

News

Price Target

Analyst Ratings

COIN

Oppenheimer Maintains Outperform on Coinbase Glb, Raises Price Target to $358

RBC Capital analyst Scott Hanold maintains Range Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RRC#NYSE">RRC</a>) with a Sector Perform and raises the price target from $35 to $40.

RBC Capital Maintains Sector Perform on Range Resources, Raises Price Target to $40

Oppenheimer analyst Rupesh Parikh reiterates Target (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGT#NYSE">TGT</a>) with a Outperform and maintains $165 price target.

Reiteration

Oppenheimer Reiterates Outperform on Target, Maintains $165 Price Target

Alphabet, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) and the U.S. Department of Justice are set to present closing arguments on Monday in a trial to determine if Google&#8217;s advertising technology<a href="https://www.benzinga.com/government/regulations/24/11/42143421/staggering-google-breakup-proposal-from-doj-a-kitchen-sink-moment-alphabet-analyst"> constitutes an illegal monopoly.</a>
The Details: The DOJ alleges Google maintains a monopoly in "open-web display advertising" by dominating all aspects of the marketplace with a funnel of technologies that match online publishers to advertisers as well as controls the ad exchange market, which matches the buy side to the sell side.&nbsp;
"One monopoly is bad enough. But a trifecta of monopolies is what we have here," Justice Department lawyer Julia Tarver Wood said during her opening statement.
Read More: <a href="https://www.benzinga.com/general/social-media/24/11/42119493/rumble-eyes-buying-bitcoin-could-it-be-the-next-microstrategy">Rumble CEO Considers Bitcoin Investment, Engages Michael Saylor As Shares Rally</a>
Google says that the DOJ's case is focused on a narrow niche of digital advertising and that the company's market share of 25% has been decreasing as competition has increased in the space.&nbsp;
According to the AP, court documents show that Google argues the government's case "boil(s) down to the persistent complaints of a handful of Google's rivals and several mammoth publishers."
The case is being heard by U.S. District Judge Leonie Brinkema, in Alexandria, Virginia, who is expected to decide the case and issue a written ruling by the end of the year.&nbsp;
What Else: A District of Columbia judge, in a separate case, ruled in August that Google's search engine business does constitute a monopoly. The DOJ presented its proposed remedies last week, which included the requirement for Alphabet to divest Google Chrome, the internet&#8217;s leading browser with over 60% market share globally.
Other <a href="https://www.benzinga.com/government/regulations/24/11/42119020/alphabet-bleeds-over-120-billion-in-market-value-eyes-worst-day-in-10-months-after-doj-demands-google-chrome-sale#google_vignette">proposals included</a> forcing Google to share search data with competitors, and ending default search agreements, which make Google the automatic search engine on devices and web browsers like Apple&#8217;s Safari.
&#8220;Google&#8217;s unlawful behavior has deprived rivals not only of critical distribution channels but also distribution partners who could otherwise enable entry into these markets by competitors in new and innovative ways,&#8221; the DOJ said in a statement.
The judge is expected to deliver a final decision in that case next summer.&nbsp;
Price Action: According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Alphabet shares are up 1.92% at $167.92 at the time of publication Monday. 
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/etfs/24/11/42044642/trump-appears-frustrated-as-elon-musk-chimes-in-on-treasury-secretary-adds-more-names-to-a-list-of-potential-picks">Trump Appears &#8216;Frustrated&#8217; As Elon Musk Chimes In On Treasury Secretary, Adds More Names To Short List&nbsp;</a></li>
</ul>
Image: Shutterstock

Large Cap

Legal

Movers

Tech

GOOG

GOOGL

Google, DOJ Present Closing Arguments In AdTech Trial Monday

RBC Capital analyst Gregory Renza maintains Perspective Therapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CATX#AMEX">CATX</a>) with a Outperform and lowers the price target from $25 to $16.

CATX

RBC Capital Maintains Outperform on Perspective Therapeutics, Lowers Price Target to $16

WIIM

RNAZ

TransCode Therapeutics shares are trading lower after the company announced a 1-for-33 reverse stock split.

Wells Fargo analyst Roger Read maintains EQT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EQT#NYSE">EQT</a>) with a Overweight and raises the price target from $42 to $52.

Wells Fargo Maintains Overweight on EQT, Raises Price Target to $52

Analog Devices's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADI#NYSE">ADI</a>) short percent of float has fallen 21.05% since its last report. The company recently reported that it has 7.43 million shares sold short, which is 1.5% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.07 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Analog Devices Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732549520_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Analog Devices has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Analog Devices's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Analog Devices's peer group average for short interest as a percentage of float is 4.84%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

Peering Into Analog Devices's Recent Short Interest

Old National's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ONB#NYSE">ONB</a>) short percent of float has risen 7.32% since its last report. The company recently reported that it has 9.46 million shares sold short, which is 3.81% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.3 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Old National Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732549515_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Old National has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Old National's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Old National's peer group average for short interest as a percentage of float is 3.09%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Looking Into Old National's Recent Short Interest

Time's running out. The Biden administration is in a mad dash to finalize billions in CHIPS Act deals before Trump takes office. With $39 billion in funding at stake, there's no room for delays.
The CHIPS Act, signed in 2022, was supposed to bring <a href="https://www.benzinga.com/markets/equities/24/10/41387939/chipmakers-rally-nvidia-smashes-records-on-tsmc-blowout-earnings-gold-hit-all-time-highs-whats-d">chip production</a> home. The goal? Secure supply chains and cut reliance on Taiwan for advanced semiconductors. It's a big deal for U.S. manufacturing. But there's a catch. While 90% of the money is allocated, most of it hasn't been locked down yet. Only two deals, worth $6.6 billion, are fully finalized, <a href="https://www.commerce.gov/news/press-releases/2024/11/biden-harris-administration-announces-chips-incentives-award-tsmc">according to the Commerce Department.</a>
Don't Miss:
<ul>
<li>Inspired by Uber and Airbnb &#8211; Deloitte's fastest-growing software company is transforming 7 billion smartphones into income-generating assets &#8211; <a href="https://www.benzinga.com/money/mode-mobile-2">with $1,000 you can invest at just $0.26/share!</a></li>
<li>The global games market is projected to generate $272B by the end of the year —<a href="https://www.benzinga.com/money/gameflip"> for $0.55/share, this VC-backed startup with a 7M+ userbase gives investors easy access to this asset market.</a></li>
</ul>
Commerce Secretary Gina Raimondo promised to allocate every dollar by the end of the year. But progress? It's been slow. And patience is wearing thin. "We are disappointed by how long and how slow the dispensing of funds has been," said Intel CEO Pat Gelsinger, as reported by Bloomberg. He's frustrated. The process has dragged on for over two years.
President Joe Biden's team is trying to speed things up. Last week, they announced<a href="https://www.benzinga.com/government/regulations/24/11/42011035/just-before-bidens-term-ends-taiwan-semiconductor-lands-6-6-billion-in-us-funding-to-build-advanced-chip-plants"> a $6.6 billion deal </a>with Taiwan's TSMC. At least $1 billion should roll out before the year ends. But there's still a lot left to sort out. Intel, the biggest potential recipient, is still negotiating terms to unlock its share.
President-elect Donald Trump, meanwhile, isn't a fan of the CHIPS Act. He's been vocal. He thinks tariffs are a better way to push companies to make chips here. On a podcast with Joe Rogan, he called tariffs the smarter move. His team might shift gears when he takes office. But here's the thing: once a CHIPS Act deal is finalized, it's tough to undo. They're legally binding unless companies don't hold up their end of the bargain.
Trending: This Jeff Bezos-backed startup will allow you to <a href="https://www.benzinga.com/money/bezos-landlord-100-dollars">become a landlord in just 10 minutes, with minimum investments as low as $100 for properties like the Byer House from Stranger Things.</a>
Analysts like Jeff Koch say Trump could slow things down, even if he doesn't scrap the CHIPS Act. "This had the ancillary benefit of pushing the Biden administration to cut through red tape and disburse CHIPS Act funds while still in power," Koch told Business Insider.
There's also pressure from the clock. January is fast approaching. Biden's team knows the window to finalize these agreements is closing. The next administration could stall or rewrite the rules, adding more uncertainty to a complicated process.
And it's not just about securing funding. There are benchmarks. <a href="https://www.benzinga.com/news/earnings/24/10/41654832/intel-likely-to-report-q3-loss-these-most-accurate-analysts-revise-forecasts-ahead-of-earnings-call">Companies like Intel </a>need clear terms to access the money. Another layer of bureaucracy is slowing things down. For Biden, it's a race against time to solidify the vision of the CHIPS Act before Trump's team takes over.
The stakes are high. America needs these funds locked in to compete globally. Chips power everything from smartphones to cars, so falling behind isn't an option. All eyes are on whether Biden can pull this off in time. The pressure's on and there's no room for missteps.
Read Next:
<ul>
<li>Studies show 50% of consumers think Financial Advisors cost much more than they do —<a href="https://www.benzinga.com/money/money-pickle"> to debunk this, this company provides matching for free and a complimentary first call with the matched advisor.</a></li>
<li>‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2">You can invest TODAY for just $0.26/share with a $1000 minimum.</a></li>
</ul>

Startups

'We Are Disappointed.' Intel CEO Criticizes Delays As Biden Pushes $6.6 Billion To TSMC

Zebra Technologies's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZBRA#NYSE">ZBRA</a>) short percent of float has fallen 17.52% since its last report. The company recently reported that it has 511 thousand shares sold short, which is 1.13% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.07 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Zebra Technologies Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732549510_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Zebra Technologies has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Zebra Technologies's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Zebra Technologies's peer group average for short interest as a percentage of float is 6.77%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

ZBRA

Looking Into Zebra Technologies's Recent Short Interest

Diana Shipping shares are trading lower after the company reported worse-than-expected Q3 sales results.

IMUX

Immunic shares are trading higher after HC Wainwright initiated coverage on the stock with a Buy rating and announced a $10 price target.

Wells Fargo maintains Expand Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXE#NASDAQ">EXE</a>) with a Equal-Weight and raises the price target from $83 to $100.

Wells Fargo Maintains Equal-Weight on Expand Energy, Raises Price Target to $100

Palatin Technologies shares are trading higher after the company announced the completion of enrollment in its Phase 2 Study of PL8177.

Editor's Note: The headline has been corrected to accurately reflect the quoted material.
Elon Musk on Saturday shared a cryptic tweet on X, hinting at a significant turning point in human history.
What Happened: Musk&nbsp;responded to a post on X by Bojan Tunguz, which referred to an unspecified event as &#8220;one of the major inflection&nbsp;points of human history.&#8221; Musk&#8217;s reply was enigmatic, stating, &#8220;I knew if I brought&nbsp;a sink they would have&nbsp;to let that sink in.&nbsp;How could they not?&#8221;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">I knew if I brought a sink they would have to let that sink in. How could they not? <a href="https://t.co/voEVBMC7Ht">https://t.co/voEVBMC7Ht</a>
&mdash; Elon Musk (@elonmusk) <a href="https://twitter.com/elonmusk/status/1860199022121943545?ref_src=twsrc%5Etfw">November 23, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
The Tesla and SpaceX CEO&#8217;s post on X has left his followers intrigued, as they attempt to decipher the meaning behind his cryptic words.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42152684/musk-tweet-sparks-dogecoin-surge-fuels-speculation-on-x-payments">Musk Tweet Sparks Dogecoin Surge, Fuels Speculation On X Payments</a>
Why It Matters: Musk is known for his cryptic tweets, which often lead to widespread speculation. His recent tweet, which suggests a significant turning point in human history, has sparked a flurry of theories among his followers.
While the exact meaning behind Musk&#8217;s tweet remains unclear, it underscores his reputation as a thought leader in the tech industry, known for pushing boundaries and challenging conventional thinking.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/tech/24/11/42152586/judge-rejects-sec-bid-to-penalize-musk-over-missed-deposition">Judge Rejects SEC Bid to Penalize Musk Over Missed Deposition</a></li>
</ul>
Photo: Shutterstock

Social Media

'I Knew If I Brought A Sink': What Does Elon Musk's Cryptic Tweet Mean? (CORRECTED)

B of A Securities analyst Omar Dessouky maintains AppLovin (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APP#NASDAQ">APP</a>) with a Buy and raises the price target from $252 to $375.

B of A Securities Maintains Buy on AppLovin, Raises Price Target to $375

Elon Musk recently set social media abuzz with a tweet featuring a clip from Netflix&#8217;s &#8220;Narcos,&#8221; where Pablo Escobar, portrayed by actor Wagner Moura, is seen smoking a joint. Musk captioned the post, &#8220;Actual footage of me after @realDonaldTrump won,&#8221; referring to <a href="https://www.benzinga.com/news/24/11/41768178/donald-trump-defeats-kamala-harris-to-win-2024-election">Donald Trump&#8217;s 2024 victory</a>. The tweet&#8217;s provocative nature, tying a drug kingpin character to a political celebration, triggered a range of reactions online.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Actual footage of me after <a href="https://twitter.com/realDonaldTrump?ref_src=twsrc%5Etfw">@realDonaldTrump</a> won <a href="https://t.co/PhPJjzaw0J">pic.twitter.com/PhPJjzaw0J</a>
&mdash; Elon Musk (@elonmusk) <a href="https://twitter.com/elonmusk/status/1860475842800812347?ref_src=twsrc%5Etfw">November 24, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
<h3 class="wp-block-heading">Musk's Cannabis Advocacy And Public Persona</h3>
Musk's selection of a cannabis-themed scene aligns with his public stance on marijuana and psychedelics. In 2018, Musk famously smoked a joint during a live appearance on &#8220;The Joe Rogan Experience,&#8221; sparking both cultural fascination and corporate scrutiny. The incident even prompted NASA to review SpaceX's workplace practices.
Beyond this, Musk has consistently supported the legalization of <a href="https://www.benzinga.com/cannabis">cannabis</a> and the therapeutic use of <a href="https://www.benzinga.com/topic/psychedelics">psychedelics</a>, recently describing them as "pretty helpful" for conditions like PTSD and depression. His tweet juxtaposes this advocacy with a tongue-in-cheek nod to cannabis culture, though some critics have questioned the appropriateness of invoking Escobar&#8217;s likeness in the context of drug reform.
<h3 class="wp-block-heading">Musk's Role In Trump's Reelection And Political Context</h3>
The tweet coincides with Musk's increasing prominence in U.S. politics. As co-leader of the Department of Government Efficiency (DOGE), a special initiative within President-elect Donald Trump's upcoming administration, Musk is tasked with identifying waste in federal operations and driving cost-cutting measures.
See also: <a href="https://www.benzinga.com/markets/cannabis/24/11/41951578/trump-taps-cannabis-supporters-elon-musk-vivek-ramaswamy-to-slash-government-spending">Trump Taps Cannabis Supporters Elon Musk, Vivek Ramaswamy To Slash Government Spending</a>
The role cements Musk's alignment with Trump's deregulatory platform, but his cannabis-friendly public image contrasts sharply with conservative perspectives on drug policy.
<h3 class="wp-block-heading">Wagner Moura's Political Views And Social Media Irony</h3>
Wagner Moura, the Brazilian actor known for his portrayal of Escobar in &#8220;Narcos,&#8221; holds progressive political views that contrast with Musk's alignment with Trump. Moura has openly <a href="https://www.yahoo.com/entertainment/wagner-moura-chasing-truth-100000406.html?utm_source=chatgpt.com&amp;guccounter=1&amp;guce_referrer=aHR0cHM6Ly9jaGF0Z3B0LmNvbS8&amp;guce_referrer_sig=AQAAAHyPGwAKPhq_ebbbAr72fKnwcPnvJS6EpQAlbqiXcPZejVhUfydhaxYD39x4-d1Xi4IZ9CYMdVNt30qS4HKVbbOP2T71GtilDmAimDnHraRNLm8zAuS3LxtiLjwBvSDS9Veg3PKX0XNT33KTYuXeq4qsqFCIZYHrN8nkqE3v-2vh">supported</a> leftist causes in Brazil and has been an outspoken critic of authoritarianism. While he has not directly criticized Trump on record, his advocacy for democratic values and opposition to leaders like Brazil's former president Jair Bolsonaro suggest ideological differences with Trump's approach.
This clash between Moura and Musk was not lost on social media. One Twitter user noted, "This actor is Brazilian. He hates Donald Trump and loves Fidel Castro," while another added, "This actor is Brazilian, liberal, and deeply hates you, Elon." Moura has not publicly commented on the incident, but the online reactions pointed out the irony of Musk's use of the clip
Photo by <a href="https://commons.wikimedia.org/wiki/User:Dmoberhaus">Daniel Oberhaus</a> via <a href="https://commons.wikimedia.org/wiki/File:Elon_Musk_at_a_Press_Conference.jpg">Wikimedia Commons</a>, edited by Benzinga

Cannabis

Politics

Did Elon Musk Really Use A Meme Of Pablo Escobar Smoking Weed To Celebrate Trump's Election Victory? What Does It Even Mean?

QNTM

Quantum BioPharma shares are trading higher after the company announced legal teams have been assembled to pursue the recovery of all losses and damages.

RBC Capital analyst Christopher Dendrinos maintains GE Vernova (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GEV#NYSE">GEV</a>) with a Outperform and raises the price target from $285 to $376.

RBC Capital Maintains Outperform on GE Vernova, Raises Price Target to $376

Needham analyst Serge Belanger has maintained their bullish stance on CLSD stock, giving a Buy rating today. Serge Belanger has given his Buy ratin...

Buy Rating Affirmed with Increased Price Target for Clearside Biomedical Post-ODYSSEY Trial Success

Clearside stock falls 12% amid Phase 2 data for CLS-AX

Analyst Debanjana Chatterjee from JonesTrading reiterated a Buy rating on Clearside Biomedical (CLSD – Research Report) and keeping the price targe...

Clearside Biomedical's CLS-AX Shows Promising Phase 2b Results for Wet AMD, Justifying a Buy Rating with a $6.00 Target

Clearside Biomedical (CLSD) announced that multiple presentations were delivered at the 2024 Annual Meeting of the American Academy of Ophthalmolog...

Clearside Biomedical announces multiple presentations delivered at 2024 AAO

Clearside Biomedical GAAP EPS of -$0.10 beats by $0.02, revenue of $1.03M beats by $0.91M

Reports Q3 revenue $1.04M, consensus $120,000. "We are making outstanding progress advancing our differentiated suprachoroidal delivery pipeline," ...

Clearside Biomedical reports Q3 EPS (10c), consensus (12c)

Clearside Biomedical, Inc. (CLSD) Q3 2024 Earnings Conference Call Transcript

Clearside Biomedical Inc ( ($CLSD) ) has released its Q3 earnings. Here is a breakdown of the information Clearside Biomedical Inc presented to its...

Clearside Biomedical Reports Positive Q3 2024 Results

Clearside Biomedical (CLSD – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Debanjana Chatt...

Promising Outlook for Clearside Biomedical: Buy Rating Backed by Strong Phase 2b ODYSSEY Trial Data and Robust Cash Position

Clearside Biomedical (CLSD) announced that presentations highlighting Clearside's suprachoroidal delivery technology and data on its pipeline progr...

Clearside extends global footprint with presentations at medical meetings

CLSD

Earnings

Press Releases

Clearside Biomedical Announces Second Quarter 2024 Financial Results and Provides Corporate Update

Clearside Biomedical Announces Completion of Final Participant Visit in ODYSSEY Phase 2b Trial of CLS-AX in Wet AMD

Health Care

Clearside Biomedical Announces Positive Topline Results from ODYSSEY Phase 2b Trial of Suprachoroidal CLS-AX in Wet AMD Achieving All Primary and Secondary Outcomes

Clearside Biomedical's Positive ODYSSEY Wet AMD Data and Suprachoroidal Injection Platform Highlighted in Presentations at Multiple Events During AAO 2024 Annual Meeting

Clearside Biomedical to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Tuesday, November 12, 2024

Management

Clearside Biomedical Appoints Tony Gibney as New Chair of the Board of Directors

Clearside Biomedical to Participate in Fireside Chat at the Stifel 2024 Healthcare Conference

Clearside Biomedical Partner Arctic Vision Executes Commercial Collaboration Agreement with Santen Pharmaceutical Co., Ltd for ARVN001 Suprachoroidal Space Injection Therapy for the Treatment of Uveitic Macular Edema

Comments

Clearside Biomedical

Clearside Biomedical (CLSD) Opzioni

Clearside Biomedical (NASDAQ:CLSD) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO